Resona Asset Management Co. Ltd. Invests $26.51 Million in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Resona Asset Management Co. Ltd. bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 37,211 shares of the biopharmaceutical company's stock, valued at approximately $26,507,000.

A number of other hedge funds have also recently modified their holdings of REGN. Norges Bank purchased a new position in shares of Regeneron Pharmaceuticals during the fourth quarter worth approximately $802,036,000. Amundi grew its position in Regeneron Pharmaceuticals by 45.8% during the 4th quarter. Amundi now owns 1,551,735 shares of the biopharmaceutical company's stock worth $1,138,074,000 after purchasing an additional 487,489 shares during the last quarter. Loomis Sayles & Co. L P increased its stake in Regeneron Pharmaceuticals by 33.4% in the fourth quarter. Loomis Sayles & Co. L P now owns 1,575,349 shares of the biopharmaceutical company's stock valued at $1,122,168,000 after purchasing an additional 393,997 shares during the period. Proficio Capital Partners LLC raised its holdings in shares of Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock valued at $156,284,000 after buying an additional 219,162 shares during the last quarter. Finally, Geode Capital Management LLC boosted its stake in shares of Regeneron Pharmaceuticals by 6.8% during the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock worth $1,726,940,000 after buying an additional 155,369 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

REGN has been the subject of a number of recent research reports. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, December 17th. Sanford C. Bernstein cut their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an "outperform" rating for the company in a research note on Tuesday, January 7th. UBS Group downgraded Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price target for the company from $1,130.00 to $738.00 in a research note on Thursday, January 16th. Finally, Leerink Partners upgraded Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and increased their price objective for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $966.88.

Regeneron Pharmaceuticals Trading Down 1.1 %

Shares of REGN stock traded down $5.87 during mid-day trading on Friday, hitting $540.53. 375,210 shares of the company's stock were exchanged, compared to its average volume of 704,165. The stock has a market cap of $59.09 billion, a price-to-earnings ratio of 14.14, a PEG ratio of 2.34 and a beta of 0.44. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $525.99 and a fifty-two week high of $1,211.20. The stock has a 50-day simple moving average of $662.80 and a two-hundred day simple moving average of $758.54.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts' consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm had revenue of $3.79 billion for the quarter, compared to analysts' expectations of $3.76 billion. During the same period in the previous year, the company posted $11.86 earnings per share. Regeneron Pharmaceuticals's revenue was up 10.3% compared to the same quarter last year. Equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 annualized dividend and a dividend yield of 0.65%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.